TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
4SC AG ( (DE:VSC) ) has issued an announcement.
4SC AG announced that the European Medicines Agency (EMA) is expected to issue a negative opinion on the Marketing Authorization Application for Resminostat (Kinselby), a treatment for advanced stage cutaneous T-cell lymphoma (CTCL). As a result, 4SC has decided to discontinue the development and commercialization of Resminostat. The company plans to reassess its strategic direction and has assured stakeholders that it has sufficient funds to cover its projected expenses for at least the next 12 months.
More about 4SC AG
4SC AG is a biotechnology company based in Planegg-Martinsried, Germany, focused on developing small molecule drugs for the treatment of cancer and autoimmune diseases. The company is listed on the Frankfurt Stock Exchange and is known for its research and development efforts in oncology.
Average Trading Volume: 1,048
Technical Sentiment Signal: Sell
Current Market Cap: €35.01M
Find detailed analytics on VSC stock on TipRanks’ Stock Analysis page.